Sign up Australia
Proactive Investors - Run By Investors For Investors

The Hydroponics Company gets a lift following medicinal cannabis export approval

On track for a pilot cannabis growing program targeted for first half of 2018.
cannabis cultivation
Build out of the growing facility is well advanced

The Hydroponics Company Ltd’s (ASX:THC) shares are trading circa 12% higher intra-day at $1.04 following the federal government’s decision to allow medicinal cannabis to be exported from Australia.

David Radford, chief executive officer, said: “this federal government initiative supports the growth and further investment in Australian medicinal cannabis companies.

“THC is uniquely placed to both develop the international opportunities that will now open up through our international partnerships, as well as accelerate the Australian uptake of medicinal cannabis through our National Access Cannabis clinics that we plan to establish, commencing in early 2018.”

New Initiative to support the local medicinal cannabis industry

The federal government has approved the exportation of medicinal cannabis in a bid to strengthen the supply of medicinal cannabis amid growing demand domestically and worldwide.

This initiative is expected to foster the development of the local medicinal cannabis industry and lead to further investments within the medicinal cannabis market in Australia.

Pilot growing program in the first half of 2018

The Hydroponics Company is on track for a pilot cannabis growing program targeted for the first half of 2018, subject to government licencing.

Importantly, the build out of the company’s growing facility in Queensland is well advanced.

READ: The Hydroponics Company’s shares surge after signing medicinal cannabis deal

The company is on track to import the first medicinal cannabis product range from Endoca early in 2018.

Endoca is one of Europe’s most highly respected suppliers of certified medicinal cannabis, with sales exceeding €50 million per annum.

The Hydroponics Company is aiming to provide access to legal medicinal cannabis for eligible medical practitioners commencing with an initial selection of Endoca CBD products (3% CBD oil, 15% CBD oil).

READ: The Hydroponics Company raises $8 million to fast-track development of medicinal cannabis in Australia

The company recently raised $8 million via a placement to sophisticated and institutional investors at $0.63 per share.

Medicinal cannabis clinics program to commence in 2018

Early in 2018, the company will commence recruitment of staff for the expansion of the National Access Cannabis (NAC) clinic model.

The clinics will provide professional education and training for referring physicians and patients, and, in parallel collect meaningful patient data to support further advancement of the programs.

View full THC profile View Profile

The Hydroponics Company Timeline

Related Articles

mri scanner
June 06 2018
It is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
affimer technology
May 01 2018
The company is making progress with its lead immuno-oncology programmes
1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use